-
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
•
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab), a humanized ADCC-enhanced anti-Claudin 18.2 monoclonal antibody (mAb), has received orphan drug designation (ODD) status from the US FDA for the treatment of pancreatic cancer. This follows a previous ODD granted in 2021 for the…
-
CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health
•
China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the Chinese Center for Disease Control and Prevention (CDC). This collaboration aims to enhance various aspects of disease prevention and public health development in China, marking a significant step forward in the nation’s healthcare strategy. Areas…
-
ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its Phase II clinical study (IMM01-02), which investigates the combination of IMM01 with azacitidine for the treatment of naïve chronic myelomonocytic leukemia (CMML). The study has fully enrolled 20 patients, marking a significant milestone in the…
-
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment in the RADIUS-HTN study for its Iberis renal radiofrequency denervation (RDN) system, marking a significant milestone in Bordeaux, France. Objectives and Design of the RADIUS-HTN StudyThe RADIUS-HTN study is designed to assess the performance of…
-
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has entered into a licensing agreement with Taiwan-based Orient EuroPharma Co., Ltd for the immunotherapy drug oregovomab. The agreement grants Orient exclusive commercialization rights to oregovomab in Taiwan, with additional preemptive rights for exclusive sales, marketing,…
-
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of proceeds from previous subscriptions. The company has decided to redirect HKD 509 million (USD 64.8 million), initially intended for the clinical development and commercialization of proxalutamide, pyrilutamide, and AR-PROTAC GT20029, away from clinical studies for…
-
Pfizer Partners with HCRC to Support ‘Healthy China’ Initiative
•
US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health China Research Center (HCRC). This long-term collaboration is aimed at supporting the “Healthy China” initiative, with a focus on several key areas including research into equitable access to basic health services, the scientific and standardized…
-
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
•
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD 660.6 million) for 2022, reflecting a 6.7% year-on-year (YOY) increase. Product revenues specifically reached RMB 4.139 billion (USD 600.9 million), up 3.4% YOY. This growth was driven by increased volumes and new product revenues, despite…
